Sage Journals: Discover world-class research

Abstract

Continuous glucose monitoring (CGM)-based metrics such as time in range and time below range (TBR) and their clinical targets are recommended along with glycated hemoglobin (A1c) to optimize diabetes care. CGM metrics are easy to understand by people with diabetes and have been widely accepted among health care providers. TBR, that is, time spent below a certain glucose level (e.g., <70 mg/dL and <54 mg/dL), is expressed as a percentage. This brief report draws attention to some limitations of TBR when expressed as an integer percentage and highlights problems introduced by rounding-off of numerical values for TBR on ambulatory glucose profile and other reports from CGM and automated insulin delivery systems that may be misleading or incorrectly interpreted. The goal of this article is to generate more discussion around reporting of TBR in ways that can be clinically impactful for people living with diabetes, health care providers, regulatory agencies, and payers to stratify and predict severe hypoglycemic events.

Get full access to this article

View all access options for this article.

References

American Diabetes Association Professional Practice Committee. Glycemic Targets: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022; 45(Suppl. 1):S83–S96; doi: 10.2337/dc22-S006.

Grunberger

, Sherr

, Allende

, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021; 27(6):505–537.

Battelino

, Danne

, Bergenstal

, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the Internatinal Consensus on Time in Range. Diabetes Care, 2019; 42(8):1593–1603.

American Diabetes Association. Time in Range. Available from: https://professional.diabetes.org/content-page/time-range [Last accessed: July 12, 2023 ].

Beck

, Raghinaru

, Calhoun

, et al. The relationship between percent time <70 mg/dL and percent time <54 mg/dL measured by continuous glucose monitoring. Diabetes Technol Ther, 2023; 25(3):157–160.

Fiallo-Scharer

, Cheng

, Beck

, et al. Factors predictive of severe hypoglycemia in type 1 diabetes: Analysis from the juvenile diabetes research foundation continuous glucose monitoring randomized control trial dataset. Diabetes Care, 2011; 34(3):586–590.

Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: A joint position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care, 2017; 40(1):155–157.

Battelino

, Alexander

, Amiel

, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol, 2023; 11(1):42–57.

Cox

, Gonder-Frederick

, Ritterband

, et al. Prediction of severe hypoglycemia. Diabetes Care, 2007; 30(6):1370–1373; doi: 10.2337/dc06-1386.

10.

Rodbard

. Metrics to evaluate quality of glycemic control: Comparison of time in target, hypoglycemic, and hyperglycemic ranges with “risk indices.”. Diabetes Technol Ther, 2018; 20(5):325–334.

Limitations of Reporting Time Below Range as a Percentage

Abstract

Get full access to this article

References